22 December 2022>: Clinical Research
Impact of the De Ritis Ratio on the Prognosis of Patients with Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
Kai Wang ABCE* , Zijun Chen ABE* , Deli Zeng BF , Maojuan Ran AEFG*DOI: 10.12659/MSM.937737
Med Sci Monit 2022; 28:e937737
Table 1 Clinical data of the study population.
Overall population | Low De Ritis ratio (n=177) | High De Ritis ratio (n=27) | p value | |
---|---|---|---|---|
Age (years), n (%) | ||||
22 (10.8) | 21 (11.9) | 1 (3.7) | ||
60–69 | 58 (28.4) | 56 (31.6) | 2 (7.4) | |
70–79 | 71 (34.8) | 61 (34.5) | 10 (37.0) | |
≥80 | 53 (26.0) | 39 (22.0) | 14 (51.9) | |
Men, n (%) | 142 (69.6) | 127 (71.8) | 15 (55.6) | 0.139 |
BMI (kg/m), n (%) | 0.002 | |||
17 (8.3) | 13 (7.3) | 4 (14.8) | ||
18.5–24.9 | 119 (58.3) | 98 (55.4) | 21 (77.8) | |
≥25.0 | 68 (33.3) | 66 (37.3) | 2 (7.4) | |
Alb (g/dL) ≥4.0, n (%) | 115 (56.4) | 106 (59.9) | 9 (33.3) | 0.017 |
Hb (g/dL) (mean (SD)) | 13.58 (2.01) | 13.80 (1.92) | 12.14 (2.02) | |
eGFR(mL/min/1.73 m) (mean [SD]) | 61.32 (24.61) | 64.09 (23.42) | 43.15 (24.92) | |
CRP (mg/dL), n (%) | 0.964 | |||
0.01–0.03 | 34 (16.7) | 30 (16.9) | 4 (14.8) | |
0.04–0.11 | 64 (31.4) | 55 (31.1) | 9 (33.3) | |
0.12–0.33 | 55 (27.0) | 47 (26.6) | 8 (29.6) | |
0.34–9.20 | 51 (25.0) | 45 (25.4) | 6 (22.2) | |
AST (mean (SD)) | 24.66 (10.93) | 24.58 (11.02) | 25.22 (10.52) | 0.776 |
ALT (mean (SD)) | 20.90 (12.19) | 22.42 (12.24) | 10.93 (5.17) | |
LVEF (mean (SD)) | 63.36 (9.88) | 63.51 (9.59) | 62.33 (11.81) | 0.564 |
OCI, n (%) | 35 (17.2) | 28 (15.8) | 7 (25.9) | 0.306 |
PAD, n (%) | 53 (26.0) | 45 (25.4) | 8 (29.6) | 0.819 |
Hypertension, n (%) | 151 (74.0) | 132 (74.6) | 19 (70.4) | 0.819 |
Diabetes mellitus, n (%) | 73 (35.8) | 65 (36.7) | 8 (29.6) | 0.617 |
Smoker, n (%) | 101 (49.5) | 94 (53.1) | 7 (25.9) | 0.015 |
Aspirin, n (%) | 202 (99.0) | 176 (99.4) | 26 (96.3) | 0.622 |
Thienopiridines, n (%) | 200 (98.0) | 174 (98.3) | 26 (96.3) | 1.000 |
Warfarin, n (%) | 5 (2.5) | 3 (1.7) | 2 (7.4) | 0.263 |
DOAC, n (%) | 21 (10.3) | 18 (10.2) | 3 (11.1) | 1.000 |
Statins, n (%) | 111 (54.4) | 101 (57.1) | 10 (37.0) | 0.082 |
ACEI/ARB, n (%) | 106 (52.0) | 90 (50.8) | 16 (59.3) | 0.543 |
βblocker, n (%) | 55 (27.0) | 46 (26.0) | 9 (33.3) | 0.57 |
MRA, n (%) | 11 (5.4) | 10 (5.6) | 1 (3.7) | 1.000 |
Bifurcation lesions, n (%) | 101 (49.5) | 85 (48.0) | 16 (59.3) | 0.378 |
Multivessel lesions, n (%) | 53 (26.0) | 47 (26.6) | 6 (22.2) | 0.808 |
LMT, n (%) | 13 (6.4) | 12 (6.8) | 1 (3.7) | 0.852 |
Calcification lesions, n (%) | 29 (14.2) | 23 (13.0) | 6 (22.2) | 0.326 |
CTO, n (%) | 12 (5.9) | 12 (6.8) | 0 (0.0) | 0.339 |
BMI – body mass index; Alb – serum albumin; Hb – hemoglobin; eGFR – estimated glomerular filtration rate; CRP – C-reactive protein; LVEF – left ventricular ejection fraction; OCI – old cerebral infarction; PAD – peripheral artery disease; DOAC – direct oral anticoagulant; MRA – mineralocorticoid receptor antagonists; LMT – left main trunk; CTO – chronic total occlusion. |